<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833675</url>
  </required_header>
  <id_info>
    <org_study_id>38RC12.210</org_study_id>
    <nct_id>NCT02833675</nct_id>
  </id_info>
  <brief_title>Determination of Specific Biomarkers of Angioneurotic Crisis</brief_title>
  <acronym>BIOBRAD</acronym>
  <official_title>Determination of Specific Biomarkers of Angioneurotic Crisis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnosis of angioedema (AE) is difficult especially in emergency room. Two forms should be
      evoked: histaminic AE (allergic or not, which represent 95% of cases) and bradykinic AE
      (hereditary or acquired deficiency, with or without C1 Inhibitor) rarer but with more severe
      prognosis. The distinction is based on clinical features (spontaneous crisis duration,
      presence of concomitant hives, atopic history...). Sometimes it could be difficult to make
      the difference. Nowadays, there is no biological marker of the crisis. The search for
      biomarkers could improve the diagnostic and therapeutic management of AE. Previous work has
      identified targets: D-dimer, C4, and VE-cadherin. We wanted to know the sensitivity and
      specificity of these markers.

      We conducted a prospective study evaluating the D-dimer assays, complement and VE-cadherin
      during an episode of AE. Three groups of patients were tested: bradykinic AE (peripheral or
      abdominal attacks), histaminic AE, and abdominal pain (non-bradykinic and non-histaminic
      etiology) at the time (day 0) and at distance from the crisis (D7).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VE CADHERIN SENSITIVITY AND SPECIFICITY</measure>
    <time_frame>7 DAYS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>D-DIMERS SENSITIVITY AND SPECIFICITY</measure>
    <time_frame>7 DAYS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C1INHIBITOR</measure>
    <time_frame>7 DAYS</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Angioedema</condition>
  <arm_group>
    <arm_group_label>bradykinin angioedema</arm_group_label>
    <description>Hereditary angioedema with or without C1Inhibitor Drug induced angiodema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Histaminergic angioedema</arm_group_label>
    <description>Allergic and non allergic angioedema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients with abdominal pain</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bradykinin and histaminergic angioedema or with abdominal pain
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histaminergic or bradykinin angioedema

          -  Abdominal pain

        Exclusion Criteria:

          -  children &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa espin</last_name>
    <role>Study Chair</role>
    <affiliation>grenbole university hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grenoble university hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygoeren-Pürsün E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan D, Rowe A, Stark D, Sur S, Tsai E, Warrington R, Waserman S, Ameratunga R, Bernstein J, Björkander J, Brosz K, Brosz J, Bygum A, Caballero T, Frank M, Fust G, Harmat G, Kanani A, Kreuz W, Levi M, Li H, Martinez-Saguer I, Moldovan D, Nagy I, Nielsen EW, Nordenfelt P, Reshef A, Rusicke E, Smith-Foltz S, Späth P, Varga L, Xiang ZY. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):24. doi: 10.1186/1710-1492-6-24.</citation>
    <PMID>20667127</PMID>
  </reference>
  <reference>
    <citation>Bluestein HM, Hoover TA, Banerji AS, Camargo CA Jr, Reshef A, Herscu P. Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department. Ann Allergy Asthma Immunol. 2009 Dec;103(6):502-7. doi: 10.1016/S1081-1206(10)60267-0.</citation>
    <PMID>20084844</PMID>
  </reference>
  <reference>
    <citation>Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000 Apr;75(4):349-54. Review.</citation>
    <PMID>10761488</PMID>
  </reference>
  <reference>
    <citation>Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992 Jul;71(4):206-15.</citation>
    <PMID>1518394</PMID>
  </reference>
  <reference>
    <citation>Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy. 2009 Feb;64(2):254-7. doi: 10.1111/j.1398-9995.2008.01859.x. Epub 2008 Dec 4.</citation>
    <PMID>19076541</PMID>
  </reference>
  <reference>
    <citation>Bouillet L, Mannic T, Arboleas M, Subileau M, Massot C, Drouet C, Huber P, Vilgrain I. Hereditary angioedema: key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation. J Allergy Clin Immunol. 2011 Jul;128(1):232-4. doi: 10.1016/j.jaci.2011.02.017. Epub 2011 Mar 24.</citation>
    <PMID>21439626</PMID>
  </reference>
  <reference>
    <citation>Grattan C, Powell S, Humphreys F; British Association of Dermatologists. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol. 2001 Apr;144(4):708-14. Review.</citation>
    <PMID>11298527</PMID>
  </reference>
  <reference>
    <citation>Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E, Cicardi B, Cicardi M. Angioedema without urticaria: a large clinical survey. CMAJ. 2006 Oct 24;175(9):1065-70.</citation>
    <PMID>17060655</PMID>
  </reference>
  <reference>
    <citation>Temiño VM, Peebles RS Jr. The spectrum and treatment of angioedema. Am J Med. 2008 Apr;121(4):282-6. doi: 10.1016/j.amjmed.2007.09.024. Review.</citation>
    <PMID>18374684</PMID>
  </reference>
  <reference>
    <citation>Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin Immunol. 2005 Jan;114(1):3-9. Review.</citation>
    <PMID>15596403</PMID>
  </reference>
  <reference>
    <citation>Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci. 2005 Sep;99(1):6-38. Review.</citation>
    <PMID>16177542</PMID>
  </reference>
  <reference>
    <citation>Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy. 2007 Aug;62(8):842-56. Review.</citation>
    <PMID>17620062</PMID>
  </reference>
  <reference>
    <citation>Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010 Sep-Oct;31(5):407-14. doi: 10.2500/aap.2010.31.3394.</citation>
    <PMID>20929608</PMID>
  </reference>
  <reference>
    <citation>Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009 Nov;161(5):1153-8. doi: 10.1111/j.1365-2133.2009.09366.x. Epub 2009 Jun 22.</citation>
    <PMID>19709101</PMID>
  </reference>
  <reference>
    <citation>Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006 Mar;119(3):267-74.</citation>
    <PMID>16490473</PMID>
  </reference>
  <reference>
    <citation>Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006 Mar;101(3):619-27. Epub 2006 Feb 8.</citation>
    <PMID>16464219</PMID>
  </reference>
  <reference>
    <citation>Craig TJ, Wasserman RL, Levy RJ, Bewtra AK, Schneider L, Packer F, Yang WH, Keinecke HO, Kiessling PC. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol. 2010 Nov;30(6):823-9. doi: 10.1007/s10875-010-9442-1. Epub 2010 Jul 16.</citation>
    <PMID>20635155</PMID>
  </reference>
  <reference>
    <citation>Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):532-41. doi: 10.1056/NEJMoa0906393. Erratum in: N Engl J Med. 2010 Oct 7;363(15):1486.</citation>
    <PMID>20818888</PMID>
  </reference>
  <reference>
    <citation>Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999 Dec;104(6):1321-2.</citation>
    <PMID>10589018</PMID>
  </reference>
  <reference>
    <citation>Wallez Y, Vilgrain I, Huber P. Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med. 2006 Feb;16(2):55-9. Review.</citation>
    <PMID>16473763</PMID>
  </reference>
  <reference>
    <citation>Hermant B, Bibert S, Concord E, Dublet B, Weidenhaupt M, Vernet T, Gulino-Debrac D. Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration. J Biol Chem. 2003 Apr 18;278(16):14002-12. Epub 2003 Feb 12.</citation>
    <PMID>12584200</PMID>
  </reference>
  <reference>
    <citation>Lambeng N, Wallez Y, Rampon C, Cand F, Christé G, Gulino-Debrac D, Vilgrain I, Huber P. Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues. Circ Res. 2005 Feb 18;96(3):384-91. Epub 2005 Jan 20.</citation>
    <PMID>15662029</PMID>
  </reference>
  <reference>
    <citation>Brevet: w/o 2008 062314 circulating ve-cadherin as a predictive marker of sensitivity or resistance to anti-tumoral treatment, and improved method for the detection of soluble proteins.</citation>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>angioedema</keyword>
  <keyword>C1Inhibitor</keyword>
  <keyword>bradykinin</keyword>
  <keyword>Histamin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradykinin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

